Last reviewed · How we verify
NCT04476459
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
Phase 1, PHASE2 trial testing Camrelizumab in Diffuse Large B Cell Lymphoma in 33 participants. Status unknown.
1 August 2022
Quick facts
| Lead sponsor | Huiqiang Huang |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 33 |
| Start date | 23 July 2020 |
| Primary completion | 1 August 2022 |
| Estimated completion | 1 August 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Camrelizumab — full drug profile →
- Apatinib (Apatinib) — full drug profile →
Conditions studied
- Diffuse Large B Cell Lymphoma — all drugs for Diffuse Large B Cell Lymphoma →
- High-grade B-cell Lymphoma — all drugs for High-grade B-cell Lymphoma →
- Follicular Lymphoma Grade IIIb — all drugs for Follicular Lymphoma Grade IIIb →
- Transformed Lymphoma — all drugs for Transformed Lymphoma →
Sponsor
Huiqiang Huang — full company profile →
Who can join
Adults 18 to 80, any sex, with Diffuse Large B Cell Lymphoma or High-grade B-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions.
Modi D, Potugari B, Uberti J. · · 2021 · cited 29× · PMID 34830980 · DOI 10.3390/cancers13225827 -
The biology and treatment of Epstein-Barr virus-positive diffuse large B cell lymphoma, NOS.
Li JW, Deng C, Zhou XY, Deng R. · · 2024 · cited 7× · PMID 38234917 · DOI 10.1016/j.heliyon.2023.e23921
Verify or expand the search:
- PubMed search for NCT04476459
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Camrelizumab
Trials testing the same drug.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
- NCT07466901 — A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Rad · NA · not yet recruiting
- NCT07527026 — A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant T · Phase 2 · recruiting
- NCT07266350 — A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for th · not yet recruiting
Other recruiting trials for Diffuse Large B Cell Lymphoma
Currently open trials in the same condition.
- NCT06687772 — CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant · Phase 2 · recruiting
- NCT06208735 — CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · Phase 1 · recruiting
- NCT06736613 — A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma · Phase 2 · recruiting
- NCT06552572 — Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy · Phase 2 · active not recruiting
- NCT06550141 — Emapalumab Prevention of CAR-T Cell Associated Toxicities · Phase 2 · recruiting
Other Huiqiang Huang trials
Trials by the same sponsor.
- NCT04796857 — Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL · Phase 1, PHASE2 · unknown
- NCT04514393 — Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma · Phase 2 · unknown
- NCT04058470 — Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma · Phase 1, PHASE2 · unknown
- NCT04246359 — Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma · Phase 2 · unknown
- NCT03820596 — Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04476459 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Huiqiang Huang
- Last refreshed: 15 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04476459.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing